Alto Neuroscience (NYSE:ANRO) Reaches New 1-Year High – Time to Buy?

Alto Neuroscience, Inc. (NYSE:ANRO)’s stock price hit a new 52-week high during trading on Monday . The company traded as high as $21.70 and last traded at $21.22, with a volume of 90206 shares. The stock had previously closed at $20.76.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. Robert W. Baird upped their target price on shares of Alto Neuroscience from $16.00 to $22.00 and gave the company an “outperform” rating in a research report on Thursday, November 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Alto Neuroscience in a research report on Monday, December 29th. Wall Street Zen raised Alto Neuroscience from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. Chardan Capital upped their price objective on Alto Neuroscience from $15.00 to $30.00 and gave the company a “buy” rating in a research report on Monday, January 5th. Finally, BTIG Research raised their price objective on Alto Neuroscience from $27.00 to $28.00 and gave the company a “buy” rating in a research note on Tuesday, February 17th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $26.50.

Alto Neuroscience Price Performance

The firm has a market cap of $660.86 million, a P/E ratio of -9.29 and a beta of 2.51. The company has a debt-to-equity ratio of 0.20, a current ratio of 15.42 and a quick ratio of 15.42. The stock’s 50-day simple moving average is $17.37 and its two-hundred day simple moving average is $12.44.

Hedge Funds Weigh In On Alto Neuroscience

Several hedge funds have recently added to or reduced their stakes in the company. XTX Topco Ltd raised its position in Alto Neuroscience by 32.2% in the 4th quarter. XTX Topco Ltd now owns 20,824 shares of the company’s stock worth $371,000 after purchasing an additional 5,078 shares during the period. Ikarian Capital LLC boosted its position in shares of Alto Neuroscience by 368.2% during the fourth quarter. Ikarian Capital LLC now owns 515,000 shares of the company’s stock valued at $9,167,000 after buying an additional 405,000 shares during the period. Vestal Point Capital LP boosted its position in shares of Alto Neuroscience by 161.6% during the fourth quarter. Vestal Point Capital LP now owns 2,485,000 shares of the company’s stock valued at $44,233,000 after buying an additional 1,535,000 shares during the period. Wellington Management Group LLP bought a new position in shares of Alto Neuroscience during the fourth quarter valued at approximately $1,228,000. Finally, Perceptive Advisors LLC grew its stake in shares of Alto Neuroscience by 1,048.5% during the fourth quarter. Perceptive Advisors LLC now owns 1,784,393 shares of the company’s stock valued at $31,762,000 after buying an additional 1,629,027 shares during the last quarter.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.